Enhancing GABA's ability to modulate immune responses

US11992495B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• Daniel L. Kaufman · Santa Monica, US
• Jide Tian · Los Angeles, US

Key dates

• Filing date: Jun 20, 2018
• Grant date: May 28, 2024
• Expiry date: Jun 20, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Embodiments methods of reducing an inflammatory immune response (e.g., inhibiting a Th1 response) and/or promoting a regulatory immune response (e.g., enhancing Treg(s)) in a mammal are provided where the method methods involve administering to the mammal a GABAA receptor positive allosteric modulator (PAM) in an amount sufficient to reduce an inflammatory immune response and/or to promote a regulatory immune response said mammal. In certain embodiments the PAM is administered in conjunction with a GABA receptor activating ligand (e.g., GABA).